Lebrikizumab, mirikizumab, donanemab, and recently-approved Jaypirca (pirtobrutinib) for mantle cell lymphoma were all marked down for a launch in 2022 and, along with Mounjaro (tirzepatide ...

The study found that the price tag for the second-generation Bruton tyrosine kinase inhibitor would need to be reduced by 30% in order to be cost-effective compared with bendamustine-rituximab (R ...

Expert Rev Hematol. 2013;6(4):441-449. In conclusion, although age should generally determine the goal of treatment in CLL, the patient's functional status rather than chronological age can be ...